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Available online 22 August 2005

Abstract
DNA vaccines for Rift Valley fever virus (RVFV), Crimean Congo hemorrhagic fever virus (CCHFV), tick-borne encephalitis virus (TBEV),
and Hantaan virus (HTNV), were tested in mice alone or in various combinations. The bunyavirus vaccines (RVFV, CCHFV, and HTNV)
expressed Gn and Gc genes, and the flavivirus vaccine (TBEV) expressed the preM and E genes. All vaccines were delivered by gene gun.
The TBEV DNA vaccine and the RVFV DNA vaccine elicited similar levels of antibodies and protected mice from challenge when delivered
alone or in combination with other DNAs. Although in general, the HTNV and CCHFV DNA vaccines were not very immunogenic in mice,
there were no major differences in performance when given alone or in combination with the other vaccines.
Published by Elsevier Ltd.
Keywords: DNA vaccine; Multiagent vaccine; Gene gun

1. Introduction
DNA vaccines offer tremendous promise for multiagent
use. Among the advantages of DNA vaccines are their ease
of construction, low risk, and absence of interference due
to pre-existing immunity to a vector (e.g., vaccinia virus or
adenovirus vectors). This technology, however, is still limited by effective means to deliver the DNA and a paucity of
studies demonstrating efficacy in humans. Only a few studies have explored the potential of combination DNA vaccines
in animals. We previously demonstrated that DNA vaccines
for four highly pathogenic organisms, Venezuelan equine
encephalitis virus, Ebola virus, Marburg virus, and Bacillus
anthracis were able to elicit immune responses when given
to animals individually or in combination [1]. In this report,
we expand this area of research by testing combination DNA
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vaccines for four additional, highly pathogenic viruses, Hantaan virus (HTNV), tick-borne encephalitis virus (TBEV),
Rift Valley fever virus (RVFV), and Crimean Congo hemorrhagic fever virus (CCHFV).
HTNV is the prototype of the Hantavirus genus of the
family Bunyaviridae and is one of four hantaviruses known to
cause hemorrhagic fever with renal syndrome (HFRS). HFRS
caused by HTNV infection is found exclusively in Asia, with
most cases occurring in China (reviewed in [2]). Hantaviruses
are transmitted to humans by exposure to rodents’ urine,
feces, or saliva. The disease is characterized by fever and
influenza-like symptoms, and in severe cases, shock and renal
failure. A number of inactivated vaccines for HFRS have been
developed and tested in Asia, but there is no vaccine currently approved by the U.S. Food and Drug Administration
(reviewed in [3]).
CCHFV belongs to the Nairovirus genus of the family
Bunyaviridae and causes a disease characterized by an abrupt
onset of acute febrile illness that can progress to hemorrhage, renal failure, and shock. Mortality rates for CCHF have
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ranged from 10 to 70% in various outbreaks. Transmission
usually occurs by tick-bite, but can also occur through contact
with infected animal products or by person-to-person spread
(reviewed in [4]). Evidence for the presence of CCHFV has
been collected from South Africa through sub Saharan Africa,
Eastern Europe, the Middle East and parts of China. No vaccine for CCHF has been developed.
RVFV, a member of the Phlebovirus genus of the family
Bunyaviridae, is also is found in sub Saharan Africa, thus
overlaps the endemic region of CCHF. RVFV is an important livestock pathogen causing abortion in pregnant animals,
especially ewes, and a high mortality in newborn lambs, kids,
and calves. RVF also impacts humans, as evidenced by a
recent epidemic in Saudi Arabia and Yemen [5]. Disease in
humans is characterized by an influenza-like febrile illness
and can include complications, such as retinitis leading to
blindness, and more rarely, encephalitis (reviewed in [6]).
An inactivated preparation of RVFV has been developed and
is currently available only under Investigation of New Drug
(IND) status [7,8]. There are fewer than 3000 doses of the
vaccine available, and preparation of new lots is problematic. Because RVFV is not endemic to the United States, and
is such a virulent animal pathogen, its use is controlled. In
addition, the facility that previously generated the virus for
inactivation has closed. Consequently, alternative means for
producing a vaccine have been explored. Toward this goal,
a mutagenized, live-attenuated strain of RVFV, MP12, was
developed and tested in mice, sheep, and cows [9–13]. This
vaccine was quite promising in studies to assess its safety and
efficacy; however, this vaccine has not yet been licensed.
TBEV is a member of the family Flaviviridae. Human
disease is characterized first by a febrile illness, which is followed by CNS involvement in 20–30% of cases (reviewed in
[14]). Tick-borne encephalitis occurs in all countries of Central and Eastern Europe as well as in Scandinavia, France,
Italy, Greece, and Albania (reviewed in [14]). A formalininactivated, chick embryo-derived vaccine was introduced
into parts of Europe in 1976 and has resulted in a notable
decline in disease. Despite the success of this vaccine, it
suffers the disadvantages commonly associated with inactivated virus vaccines, such as the requirement for large-scale
production and purification of a highly infectious human
pathogen, the risk of incomplete inactivation of the virus,
and the need to deliver the vaccine with adjuvant in a threeshot series [15]. Also, this vaccine is not licensed for use in
the United States.
We previously reported constructing and testing DNA
vaccines for HTNV and TBEV in animals. The HTNV vaccine expresses the complement of the medium (M) genome
segment of the virus, which encodes the two viral glycoproteins Gn and Gc (referring to the amino- or carboxy-terminal
encoded protein in the polyprotein precursor, and formerly
designated G1 and G2). To gauge protective immunity, we use
a hamster infection model in which we measure neutralizing
antibody responses to the viral envelope glycoproteins after
gene gun inoculation of the DNA vaccine, and then measure

the absence of antibodies to the nucleocapsid protein (which
is not a component of the vaccine) after challenge with the
hantavirus [16]. We have shown that the HTNV DNA vaccine
induces high levels of neutralizing antibodies in hamsters and
completely protects them from challenge (i.e., confers sterile
immunity) [16,17]. In addition, we found that in monkeys,
the vaccine induces high levels of neutralizing antibodies,
which persist for many months after vaccination [17,18].
The TBEV DNA vaccine expresses the preM and E genes
of a central European isolate of TBEV (Hypr strain) [19]. We
previously demonstrated that this vaccine confers protective
immunity to mice for at least 1 year after vaccination [19], and
elicits high levels of neutralizing antibodies in monkeys [20].
Passive transfer of sera from vaccinated monkeys protects
mice from lethal challenge with TBEV [20].
DNA vaccines for RVFV have not yet been reported.
We demonstrated in earlier studies that injecting mice with
baculovirus-expressed RVFV M segment products elicited
protective immunity [21]. Similarly, infecting mice with a
recombinant vaccinia virus expressing the M segment of
RVFV elicited protection from RVFV challenge [22]. In
addition, passive transfer of neutralizing antibodies to either
Gn or Gc protected mice from challenge with RVFV [23].
Consequently, the DNA vaccines that we developed for the
studies reported here, express the M genome segment of
the virus.
To date, there have been no reports of recombinant DNA
vaccines for CCHFV. As for other viruses in the family, we
surmised that the M segment expression products would be
the most likely candidates for eliciting protective immunity.
Unlike those of other viruses in the family, however, the M
segment precursor of CCHFV Gn and Gc has been found
to undergo at least two post-translational proteolytic cleavage events. A precursor of the Gn glycoprotein is cleaved at
the conserved motifs RSKR and RRLL, potentially releasing
a highly variable mucin-like domain at its amino terminus,
and a second N-terminal domain of approximately 35 kDa
(P35) as well as the 37 kDa mature Gn [24,25]. An 85 kDa
precursor of Gc has also been described [24]; however, the
cleavage events leading to the mature 75 kDa Gc protein
have not been determined. The importance of these precursor
polypeptides in viral morphogenesis or pathogenesis is not
known. For the studies reported here, we generated a DNA
vaccine construct expressing the entire M genome segment
of CCHFV.
In a recent study, monoclonal antibodies (MAbs) to
CCHFV Gc, but not to Gn, neutralized virus in plaque
reduction neutralization tests (PRNT) [26]. However, MAbs
directed against Gn were generally more effective at protecting mice from a lethal CCHFV challenge than MAbs to Gc
when administered either 24 h before or after infection even
though these Gn MAbs did not neutralize in the cell-culture
assays. In addition, not all of the Gc MAbs that neutralized
CCHFV infection in vitro conferred protection in vivo. Thus,
there was not a strict correlation between in vitro neutralization and in vivo protection [26].
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Here, we report constructing and testing in mice two
RVFV M segment DNA vaccines and an M segment DNA
vaccine for CCHFV alone or combined with the DNA vaccines for HTNV and TBEV.

Bis–Tris pre-cast gels (Invitrogen) run in MOPS buffer
(Invitrogen).

2. Materials and methods

Plasmid DNA was precipitated onto the outside surfaces
of gold beads (approximately 2 M in diameter) as described
previously [27]. The DNA loads were 0.5–1 g/mg of gold.
For studies involving the genetic adjuvants, the RVFV+NSm
DNA vaccine was mixed with plasmids individually encoding the alpha and beta subunits of cholera toxin (CT) or the
alpha and beta subunits of a labile enterotoxin from E. coli
(LT) [28] in a ratio of 2:1:1 and the mixture was precipitated onto gold beads. The DNA-coated gold was dried on
the inside walls of Tefzel tubing, which was then cut into
0.5 in sections. Female BALB/c mice (approximately 4- to
6-weeks old) were vaccinated by using the XR-1 gene gun
(Powderject Vaccines, Inc.) as reported previously [29]. For
challenge studies, mice were transferred to a biosafety level 3
(RVFV) or level 4 (TBEV) containment area and challenged
by intraperitoneal inoculation of approximately 100 LD50 of
TBEV (strain Hypr) or RVFV (strain ZH501). Mice were
observed for signs of illness and weighed daily for at least 21
days.

2.1. DNA vaccine construction
All genes were inserted into pWRG7077, a plasmid containing a cytomegalovirus immediate early promoter and a
kanamycin resistance gene [19] or a slightly modified version of that plasmid [17].
The construction of the TBEV vaccine and the HTNV
vaccine were reported earlier [17,19].
We constructed two DNA vaccines for RVFV, both of
which express the viral M genome region encoding the envelope glycoproteins, Gn and Gc, but which differ in the amount
of nonstructural M segment (NSm) coding information that
is included. To generate RVFV+NSm and RVFV−NSm , PCR
primers were designed to incorporate Not1 and EcoR1 sites
for cloning into pWRG7077 containing a multiple cloning
site inserted between the Not1 and BglII sites of the plasmid.
Segments were amplified from plasmids used previously
for constructing recombinant baculoviruses, pAcYM1R2 and pAc373-R4 [21], with the following primers:
Not1(Forward) +NSM5 GTCAGTCAGTCAGTCAGCGGCCGCATGATTGAAGGAGCT3 ;
Not1(Forward) −NSM5 GTCAGTCAGTCAGTCAGCGGCCGCATGGCAGGGATTGCA3 ; EcoR1(Reverse) 5 CAGTCAGTCAGTCAGTGAATTCACCACCCCAAATTAC3 .
The DNA vaccine for CCHFV was constructed by excising the Not1 cassette containing CCHFV, strain 10200, M
segment sequence from a pBluescript construct kindly provided by Dr. Michael Parker. The resulting fragment was then
cloned into the modified pWRG7077 using the Not1 site. The
sequence of the clone was confirmed and expression was
checked as described below.
2.2. Transient expression assays
Methods used for measuring transient expression of the
DNA vaccines were described earlier [19]. Briefly, for each
assay, 5 g of each DNA vaccine was transfected into
monolayers of COS cells plated in 6-well plates (Costar)
by using FuGENE6 (Roche) reagent (Gibco) according to
the manufacturer’s directions. At 24 h after transfection,
the medium was removed from the wells, the cells were
incubated with cysteine and methionine-deficient medium,
then radiolabeled with 35S Promix (methionine and cysteine, Amersham). Cells were lysed on ice using Zwittergent 3–14 (Calbiochem-Behring) lysis buffer and cellular
nuclei removed by centrifugation. Radiolabeled lysates were
precipitated with specific antibodies to each virus and visualized by phosphoimaging after electrophoresis in 4–12%

2.3. Preparation of gene gun cartridges, vaccination,
and challenge of mice with RVFV, or TBEV

2.4. Plaque reduction neutralization tests
Sera from vaccinated mice were incubated at 56 ◦ C for
30 min, then diluted 1:40–1:1280 in EMEM with 10% fetal
bovine serum (FBS). A viral stock of known titer was then
diluted to 1 × 103 plaque forming units (pfu)/ml in either
EMEM with 10% FBS or Hanks Balanced Salt Solution
(HBSS) + 5% FBS. An equal volume of diluted virus was
then added to each serum dilution and also to an EMEM-only
control. The tubes were incubated at 4 ◦ C overnight. The following day, 200 l of the virus/serum mixture was added to
duplicate wells containing 3- to 7-day-old Vero or Vero E6
monolayers in 6-well plates. The plates were incubated for
90 min at 37 ◦ C/5% CO2 with gentle rocking and shaking
every 15 min to distribute the inoculum over the monolayer.
At the end of the incubation period, an agarose overlay was
prepared as follows: for every 100 ml of overlay needed,
0.6 g of SeaKem ME agarose was added to 34 ml of water,
autoclaved, then held in a 60 ◦ C water bath. The following
were then mixed together, warmed, and then added to the
agarose: 50 ml 2 × EMEM, 10 ml of FBS, 4 ml l-glutamine
(200 mM), 1 ml 100 × nonessential amino acids, 1 ml of penicillin/streptomycin, and 1 ml of Amphotericin B. Each well
was overlaid with 2 ml of the overlay mixture. The plates were
then incubated for 3–7 days at 37 ◦ C/5% CO2 , after which
2 ml of secondary overlay was added to each well. This overlay was identical to the primary overlay with the exception
that only 5 ml of FBS and 5 ml of neutral red solution (Gibco)
were added. Plaques that appeared during the next 2–3
days were counted and the neutralizing antibody titers were
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calculated as a reciprocal of the highest dilution resulting in
a 50% or 80% reduction of the plaque number as compared
to the virus-only control wells.

higher level of expression with the RVFV−NSm construct
(Fig. 1A).
3.2. DNA vaccine for CCHFV

3. Results
3.1. Construction of RVFV DNA vaccines and
demonstration of expression in cell culture
Two DNA vaccines for RVFV were constructed, which
differed only in the amount of nonstructural M segment
coding information that was included. As described earlier, the M genome segment + sense RNA has four potential
translation initiation codons (ATG) upstream of the coding
information for the amino-terminal glycoprotein, Gn, and the
carboxy-terminal glycoprotein, Gc [30]. Initiation at the second ATG produces a 14 kD NSm protein as well as Gn and
Gc. Initiation at the 4th ATG results in only Gn and Gc. We
previously demonstrated that baculovirus-expressed proteins
derived from genes in which translation initiates at the 2nd
ATG (in this report referred to as RVFV+NSm ) or from the 4th
ATG (in this report referred to as RVFV−NSm ) were immunogenic in mice, [21]. In this study, we evaluated both constructs
to see if the presence of the additional NSm product would
contribute to or detract from the immunogenicity of the DNA
vaccine.
To assay for gene expression, we transfected cultured cells
with the two RVFV DNA vaccine constructs, then radiolabeled and immune precipitated expression products with
polyclonal sera to RVFV. Both constructs produced RVFV
Gn and Gc (Fig. 1A). A small amount of the NSm protein (formerly 14 kDa protein) also was precipitated from the
RVFV+NSm construct (Fig. 1A). Both constructs expressed
Gn and Gc, although it appeared that there was a slightly

The DNA vaccine for CCHFV was constructed to express
the entire M genome segment. Transfecting cells, radiolabeling, and immune precipitating the expression products revealed products of the expected sizes for mature Gn
(37 kDa) and Gc (75 kDa) and a larger product, which might
be the 140 kDa precursor of Gn [24] (Fig. 1B).
3.3. Immunogenicity of individual and combination
DNA vaccines for RVFV+NSm , CCHFV, HTNV, and
TBEV in mice
Groups of mice were vaccinated by gene gun three times
at approximately 4-week intervals with each DNA vaccine
or with a combination of DNA vaccines for RVFV, CCHFV,
HTNV, and TBEV. At each dosing, mice in the individual
vaccine groups received four gene gun administrations of the
DNA coated on gold (approximately 10 g of DNA). Mice
in the combination groups received one gene gun administration of each of the four DNA vaccines (approximately
2.5 g of each DNA, for a total of 10 g of DNA). Mice are
lethal challenge models for both RVFV and TBEV, consequently, challenges with TBEV or RVFV, but not with HTNV
or CCHFV were performed.
As expected, the mice receiving only the TBEV DNA
vaccine developed strong neutralizing antibody responses
(Fig. 2A). After challenge with TBEV, all (8/8) of these mice
remained healthy throughout 22 days of observation, as evidenced by the absence of apparent illness, and no weight loss
(Fig. 2C). Mice that received all four of the DNA vaccines also
developed strong neutralizing antibody responses to TBEV

Fig. 1. Immune precipitation of radiolabeled expression products of the RVFV and CCHFV DNA vaccines. The DNA vaccines were transfected into cultured
cells, the expression products radiolabeled, and immune precipitated using antibodies to RVFV or CCHFV. (A) Two RVFV M genome segment DNA vaccines
were compared. The RVFV−NSm construct contains coding information only for the two envelope glycoproteins, Gn and Gc. In addition to Gn and Gc, the
RVFV+NSm construct also encodes a 14 kDa nonstructural protein (NSm). A plasmid with no insert was used as a negative control (ctrl, lane 8). Antibodies
used for immune precipitation were hyperimmune mouse ascitic fluid to RVFV (H, lanes 2, 5 and 8); a monoclonal antibody to Gc (Gc, lanes 3 and 6); or a
monoclonal antibody to Gn (Gn, lanes 4 and 7). (B) Expression of a DNA vaccine containing the coding region of the M genome segment of CCHFV was
evaluated by immune precipitation using a hyperimmune mouse serum to CCHFV (H, lane 2). Products from a plasmid with no insert (ctrl, lane 3) were
precipitated by the same serum. Size markers were included to determine approximate molecular weights of expression products (M, lane 1 both figures).
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Fig. 2. Neutralizing antibody responses and protection from challenge of mice vaccinated with the TBEV DNA vaccine alone (TBEV DNA) or in combination
with the HTNV, RVFV+NSm and CCHFV DNA vaccines (All four DNAs). (A) PRNT80 titers of mice after three inoculations with the TBEV DNA vaccine
(lanes 1–8) or all of the DNA vaccines (lanes 9–22). (B) Survival of vaccinated mice and controls receiving empty plasmid (DNA controls) or no vaccine (naı̈ve
controls). (C) Percent change in weight per group of mice after challenge with TBEV.

(Fig. 2A), and upon challenge, 13/14 mice survived. We suspect that the one death was not due to the TBEV infection,
as there was no sign of illness before death and there was
no weight loss in the group of mice that included this mouse
(Fig. 2C and data not shown).
Although we have not developed an adult mouse model
for HTNV or for CCHFV infections, we were able to measure antibody responses to the vaccine in the vaccinated mice.
After three gene gun vaccinations with the HTNV DNA vaccine, we found that 3 of 10 mice in the single vaccine group
and 9 of 26 mice in the multiagent groups developed neutralizing antibodies to HTNV (PRNT50 1:40–1:80 in the single
group, 1:40–1:160 in the multiagent group, data not shown).
Pools of sera from mice with or without neutralizing antibodies were both able to immune precipitate radiolabeled,
expressed HTNV Gn and Gc, although Gc was more apparent (Fig. 3A).
Only about half of the mice that received the CCHFV
DNA vaccine, either alone or combined with other
vaccines, developed neutralizing antibodies to CCHFV
(PRNT50 < 1:40–1:160). Immune precipitation of radiolabeled proteins using pooled sera from mice given the individual or combined DNAs revealed antibody responses to Gn
and Gc (Fig. 3B).

Unexpectedly, mice vaccinated with the RVFV+NSm vaccine did not develop neutralizing antibody responses, and
only three of nine mice in the individual group and 3 of 14
mice in the multiagent group survived challenge with RVFV.
To determine if a non-neutralizing antibody response was
induced in vaccinated mice, we transfected cells with the
RVFV+NSm DNA vaccine, then radiolabeled, and immune
precipitated expression products using sera collected after
the third vaccination. We could not detect signals for Gn and
Gc in any of the vaccinated mice before challenge, although
a control immune serum did precipitate both proteins (data
not shown).
Because of the poor performance of the RVFV+NSm DNA
vaccine, we carried out two additional experiments. In one of
the experiments, we re-evaluated the RVFV+NSm DNA vaccine in conjunction with two gene gun-delivered adjuvants,
and in the second experiment, we evaluated our other RVFV
construct, RVFV−NSm .
For the adjuvant experiment, we co-administered the
RVFV+NSm vaccine with plasmids expressing the alpha and
beta subunits of either E. coli labile enterotoxin (LT) or
cholera toxin (CT) to groups of mice. Co-administration of
these genetic adjuvants has been shown to augment the Th1
cytokine responses (gamma interferon) in mice to multiple
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Fig. 3. Immune precipitation of radiolabeled, expressed HTNV or CCHFV
proteins using sera from vaccinated mice. (A) Precipitation of HTNV expression products by hyperimmune mouse ascitic fluid to HTNV (H, lane 2) or
with pooled sera from mice given only the HTNV DNA vaccine (HTNV
DNA, lanes 3, 4) or in combination with DNA vaccines for CCHFV,
RVFV+NSm , and TBEV (All four DNAs, lanes 5, 6, 7). Pooled sera from
control mice vaccinated with a plasmid with no insert served as negative
controls (ctrl, lanes 8, 9). (B) Pooled sera from mice vaccinated with the
CCHFV vaccine only (CCHFV DNA, lane 2) or with the vaccine given in
combination with DNA vaccines for HTNV, TBEV and RVFV+NSm (All
four DNAs, lane 3). Protein size markers (M) are in lane 1 of both figures.

viral antigens when co-delivered with DNA vaccines. In addition, both adjuvants also increased antibody responses and
Th2 cytokine responses (interleukin 4) to certain antigens
tested [28].
In our experiment, groups of mice were vaccinated four
times by gene gun with the RVFV+NSm DNA by itself or
mixed with the genetic adjuvants. Control groups were vaccinated with either the empty plasmid or this plasmid mixed
with the genetic adjuvants. Mice were bled 3 weeks after
the last vaccination and sera were evaluated by PRNT and
immune precipitation. The mice were then challenged with
100 LD50 of RVFV. PRNT50 titers of 1:40 or 1:80 were
measured in four of nine mice given the RVFV+NSm , but no
neutralizing antibodies were detected in mice receiving the
vaccine combined with either of the adjuvants. Survival to
challenge in the RVFV+NSm group, CT group, or LT group,
was 2/9, 3/10 and 5/10 mice, respectively (Fig. 4A). Thus,
the RVFV+NSm DNA vaccine was poorly immunogenic with
or without the adjuvants.

Fig. 4. Survival of mice vaccinated with the RVFV DNA vaccines. (A)
Groups of mice were inoculated four times with the RVFV+NSm vaccine
alone, or mixed with genetic adjuvants encoding the alpha and beta subunits
of cholera toxin (CT) or E. coli labile enterotoxin (LT). Control mice received
a plasmid with no insert (ctrl) or the empty plasmid mixed with the CT
or LT genetic adjuvants. Mice were challenged with 100 LD50 of RVFV
and survival monitored for 30 days. No changes in survival after the 18
days shown were noted. (B) Mice were vaccinated three times with the
RVFV−NSm DNA vaccine or a control plasmid with no insert (ctrl), then
challenged with 100 LD50 of RVFV. Survival was monitored for 31 days
after challenge.

In contrast to the RVFV+NSm vaccine, the RVFV−NSm
vaccine elicited neutralizing antibodies to RVFV (PRNT50
1:40–1:320) in all 10 mice receiving three gene gun vaccinations and all mice survived challenge with RVFV (Fig. 4B).
Although 3 of 10 mice in the control group survived challenge, all three showed signs of extreme illness, whereas
the RVFV−NSm -vaccinated mice appeared healthy throughout the observation period.
3.4. Immunogenicity of individual and combination
DNA vaccines for RVFV−NSm , HTNV, and TBEV in mice
To evaluate the RVFV−NSm vaccine when given in combination with two of the other vaccines, we vaccinated groups
of mice three times at 3-week intervals with two gene gun
administrations/mouse of the individual DNAs (total 5 g of
DNA) or with two gene gun inoculations per mouse of each
of the three DNA vaccines (5 g of each vaccine).
The RVFV−NSm vaccine elicited strong neutralizing antibody responses in all but one mouse in the individual group

K. Spik et al. / Vaccine 24 (2006) 4657–4666
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Fig. 6. Neutralizing antibody responses of vaccinated mice to TBEV.
PRNT50 titers of sera from mice vaccinated with the TBEV DNA vaccine alone (TBEV DNA, white bars) or combined with the RVFV−NSm and
the HTNV DNA vaccines (All three DNAs, grey-shaded bars) were determined. The stippling of the white bars and grey bars indicates data from
mice challenged with TBEV.

proteins were precipitated with sera from mice with or without neutralizing antibodies (data not shown).
Fig. 5. Neutralizing antibody responses and survival to challenge of mice
vaccinated with the RVFV−NSm DNA vaccine. (A) PRNT50 titers were determined for mice inoculated three times with the RVFV−NSm DNA vaccine
alone (RVFV−NSm DNA, white bars) or in combination with DNA vaccines
for TBEV and HTNV (All three DNAs, grey-shaded bars). Data from mice
challenged with RVFV are indicated by the stippling in the white or grey
bars. An asterisk indicates the mouse that died after challenge with RVFV.
(B) Mice vaccinated with only the RVFV−NSm DNA vaccine, with all three
DNA vaccines, or with a control plasmid with no insert (ctrl) were challenged with 1000 LD50 of RVFV and survival was monitored for 30 days,
with no changes observed after the 26 days shown.

(PRNT50 1:160–1:1280) (Fig. 5A). All 10 mice survived
challenge with RVFV. Of the mice receiving the RVFV vaccine combined with the TBEV and HTNV vaccines, 15 of
20 had neutralizing antibody responses of 1:40 or greater
(Fig. 5A). Of the 10 mice challenged with RVFV in the multiagent group, 9 survived, with the single death occurring in a
mouse with a <1:40 neutralizing antibody response (Fig. 5A
and B). All control mice became ill and 9 of 10 died (Fig. 5B).
As in the earlier experiment, mice vaccinated with the
TBEV DNA vaccine alone or in combination with other vaccines developed strong neutralizing antibody responses to
TBEV (Fig. 6) and all mice survived challenge.
Similar to results obtained with HTNV in the four-vaccine
study, 5 of 10 mice in the individual group, and 4 of 17 mice
in the multiagent groups developed neutralizing antibody
responses to HTNV (PRNT50 1:40–1:160). In the earlier
study, we only assayed pooled sera by immune precipitation
to determine if the vaccinated mice had antibodies to HTNV.
In this study, we assayed each mouse’s serum in the individual group, and pools of sera from five mice in the multiagent
groups. We found that all samples assayed precipitated radiolabeled HTNV envelope glycoproteins, and that there was
no apparent difference between the signals observed when

4. Discussion
We constructed DNA vaccines for RVFV and CCHFV and
tested their immunogenicity in mice. We further compared
these DNA vaccines in mice in combination with each other
and with DNA vaccines that we previously engineered for
HTNV and TBEV.
RVFV has a complicated natural expression strategy, with
at least two in-frame translation initiation codons used in
normal infections. Initiation at the first in-frame ATG results
in 78 kDa protein representing a fusion of the entire preglycoprotein coding region and Gn, as well as Gc. Initiation
from this ATG allows the use of a glycosylation site within
the preglycoprotein coding region, but this glycosylation is
apparently unimportant for cleavage of the 78 kDa protein
to yield NSm and Gn [31,32]. Translation from the second
ATG, which is found 37 amino acids downsteam from the
first, yields a 14 kDa NSm protein and Gn and Gc [31,32].
The glycosylation site, which is used during translation from
the first ATG, is not used in translation from the second ATG
[32]. Although it is not clear if the fourth in-frame ATG is
used by RVFV during infection, it can be used to generate
Gn and Gc in a variety of expressions systems ([21,30–33],
this report).
In our studies, we found that the RVFV−NSm construct,
which uses the fourth in-frame translation initiation codon,
was highly immunogenic in mice and elicited protective
immunity. In contrast, the RVFV+NSm vaccine, which uses
the second in-frame codon, was not immunogenic. This finding was unexpected in that both the constructs expressed in
cell culture and produced apparently similar amounts of Gn
and Gc. We do not think that this finding reflects a technical difficulty with the RVFV+NSm , in that similar results were
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obtained in two separate experiments, one with the CT and LT
genetic adjuvants, and one without them. The adjuvants did
not improve the antibody responses elicited to the RVFV+NSm
vaccine, which was not entirely unexpected. In earlier studies, influences of both sets of vectors on antibody responses
were antigen dependent and ranged from no effect to sharp
reductions in the immunoglobulin G1 (IgG1)-to-IgG2a ratios
[28]. Here, we did not assess the antibody isotypes in the
sera of vaccinated mice, thus we do not know if the adjuvants
shifted the responses from the normal Th2-type response that
we observe after gene gun vaccination of mice toward a more
Th1-type response. The LT adjuvant may have provided some
benefit in that there was a small improvement in survival
among mice that received the LT subunits along with the
RVFV+NSm vaccine (5 of 10 survived) as compared to those
that only received the RVFV+NSm vaccine (two of nine survived). We did not pursue this finding further, because of the
poor performance of the vaccine itself.
Earlier studies demonstrated that vaccinia virus-expressed
RVFV genes, which either included or eliminated the preglycoprotein coding region, trafficked normally through the
Golgi [33]. A more recent study, with a T7 expression system, confirmed these earlier results and further demonstrated
that the Golgi localization signal is found in Gn in a region
consisting of a 20 amino acid transmembrane domain and the
adjacent 28 amino acids of the cytosolic tail [34]. Although
we do not have an explanation as to why the RVFV+NSm construct would behave differently in mice than in cell culture,
the unexpected absence of immunogenicity for a construct
is something we have observed before in our studies of
hantavirus DNA vaccines. We showed that although DNA
vaccines for two hantaviruses, HTNV and Seoul virus, are
highly immunogenic in hamsters, a DNA vaccine for another
hantavirus, Andes virus (ANDV), which was constructed the
same way as the other two vaccines, failed to elicit immune
response in hamsters [18]. Interestingly, however, this ANDV
DNA vaccine was able to elicit high levels of neutralizing
antibodies in nonhuman primates [18]. Thus, there clearly
can be differences not only between cell-culture expression
and induction of immunity in animal models, but also among
different animal models.
Like RVFV, CCHFV uses a complicated and unique,
expression strategy. CCHFV and other nairoviruses, differ
from other animal viruses in the family in that they use posttranslational processing as well as co-translational processing
to generate their mature envelope glycoproteins. There is currently no information available to relate the processing events
to viral pathogenesis; therefore, in our studies, we expressed
the entire M segment coding region. In cell-culture expression assays, correct processing appears to have occurred, in
that we were able to detect polypeptides of the expected sizes
for both Gn and Gc. In addition, we were able to demonstrate that the CCHFV DNA vaccine elicited neutralizing
antibodies in some of the vaccinated mice as well as antibodies able to immune precipitate radiolabeled expression
products. Unfortunately, there is no known challenge model

for CCHFV, thus we were unable to determine if our vaccine
offered protective immunity. We currently are attempting to
generate a CCHFV that is able to kill adult mice, and if we
are successful, will retest this vaccine for protective efficacy.
In addition, we are preparing CCHFV constructs that express
each of the mature glycoproteins separately and will compare
their immunogenicity to that of the DNA vaccine described
in this report.
Adult mice are not particularly useful models for HTNV
infection. Newborn mice have been found to suffer fatal neurological disease after intracerebral [35,36] or intraperitoneal
injection of HTNV [37], but immunocompetent adult mice
generally clear the virus. One recent report, however, found
that adult mice can also suffer neurological disease and death
after intraperitoneal injection of HTNV [38]. It is not clear
why these results differ from those of earlier studies, but there
is a possibility that the virus used in the challenges had undergone some minor mutations, as evidenced by nucleotide and
amino acid sequence changes that the authors noted. As we
did not have access to this particular HTNV stock during our
studies, we did not attempt to use it for challenge; however,
it would be interesting to compare that viral stock to our own
in mice.
In our studies, we found that mice did not mount strong
neutralizing antibody responses to our HTNV DNA vaccine. In contrast, this same HTNV DNA vaccine was able to
elicit strong neutralizing antibody responses in hamsters and
monkeys [16–18,39]. Vaccinated mice did appear to develop
antibodies to HTNV detectable by immune precipitation, and
there were no obvious differences in the results from the
individual and multiagent groups. For a more comprehensive
evaluation of this HTNV DNA vaccine in a multiagent format, it will likely be necessary to perform the HTNV portions
of the study either in hamsters or in nonhuman primates.
Although mice were not a good models for the HTNV or
CCHFV DNA vaccines, they were excellent models for the
RVFV−NSm , and TBEV DNA vaccine studies. Here and in
earlier studies, we found that both mice and nonhuman primates develop high levels of neutralizing antibodies to TBEV
after DNA vaccination [19,20]. Consequently, a comparison
of the immune responses of mice to the RVFV and TBEV
vaccines in combination experiments can probably provide
the most insight into the potential for multiagent DNA vaccines for these four viruses in mice.
In both the four DNA and the three DNA vaccine experiments, the TBEV DNA vaccine elicited strong neutralizing antibody responses and protective immunity when given
alone or combined with other DNA vaccines. There did
appear to be a trend toward slightly higher responses in the
individual group versus the multiagent groups in the first
experiment; however, in the second experiment the geometric mean titers of the neutralizing antibody responses for the
groups were nearly the same. For the RVFV−NSm vaccine, in
the second study, however, there still appeared to be a trend
toward a better response in the single than in the multiagent
group with overall consistency of developing neutralizing
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antibodies as well as higher neutralizing antibody titers seen
in mice in the individual group as compared to the multiagent
groups.
Despite these apparent trends, in general, we found no
evidence for drastic diminution of immunogenicity when
the vaccines were given together as opposed to individually.
Although to our knowledge, there are no reports of interference among unrelated gene products, such as those in our
study, there have been reports of interference when two or
more genes from the same organism are used together as DNA
vaccines. For example, when DNA vaccines expressing the
L1R and A33R of vaccinia virus are delivered together into
the same cells of a mouse by gene gun (i.e., are coated on
the same gold beads), the L1R response is greatly reduced
as compared to when L1R is given by itself. However,
if the DNAs are delivered to different cells of the mouse
(DNAs coated on different gold beads), strong responses are
elicited to both gene products [40]. The authors hypothesized that the interference might be due to A33R-specific
antibodies elicited by the initial vaccination, causing a lysis
of A33R-expressing cells during subsequent boosts and, in
doing so, diminishing the boosting effect [40]. In another
study, five plasmids expressing different malaria genes were
injected into mice and immune responses measured in mice
given each plasmid separately or as a mixture of all five.
Although the mixture induced higher levels of antibodies
against whole parasites than did the individual plasmids, there
were decreased amounts of antibodies to the individual gene
products. In addition, T-cell responses were generally lower
when the mixture was given [41]. Other studies, however,
have not shown interference when similar genes are delivered (e.g., multiple HIV-1 genes from different clades [42]);
or when two genes from the same virus are given (e.g., hepatitis B surface and core genes [43]).
One obvious practical problem with drawing inferences
concerning a trend toward slightly lower immunogenicity of
our DNA vaccines when given in combination as opposed
to separately revolves around the limitations of gene gun
delivery of DNA to small animals, such as mice. With current technology, only about 2–3 g of DNA can be delivered
by a single gene gun administration. In a multiple vaccine
study, such as ours, it is only possible to give one or two
non-overlapping administrations of each vaccine per dose,
because of the small surface area available on mice. In our first
experiment, therefore, we were only able to give one administration of each vaccine to the mice receiving all four vaccines,
while the individual group mice received four administrations
per dose. In the second experiment, we attempted to normalize this by reducing the number of DNA vaccines given to
three instead of four, so that we could give two administrations of each vaccine to mice in the multiagent group as well
as in the individual groups. Even so, two administrations may
not be sufficient to provide optimal immunogenicity with
these vaccines. It is possible that more administrations per
dose (as we are able to do in larger animals), or a different method of delivery, might result in improvement both in
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the immunogenicity and the consistency of vaccination for
both groups. Further studies will be needed to support this
conjecture.
In conclusion, the study of combination DNA vaccines
is in its infancy. It is likely that empirical analysis of various
combinations of vaccines will be required to gauge their compatibility, and that new methods and models will be needed
to truly assess differences in immunogenicity that will arise
when vaccines are given in combination. In this study, we
make available for the first time, DNA vaccines for RVFV
and CCHFV, which can be further analyzed as multiagent
vaccines.
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